11 research outputs found
Intralezijska injekcija triamcinolon acetonida u lijeÄenju halaziona
The aim of the study was to evaluate the efficacy of intralesional triamcinolone acetonide injection in primary and recurrent chalazion. The study included 30 patients with primary and recurrent chalazion (37 cases) and 24 patients as a control group. Patients with primary and recurrent chalazion received intralesional injection of 0.1 to 0.2 mL triamcinolone acetonide (40 mg/mL). Control group received intralesional injection of 0.1 to 0.2 mL 0.9% NaCl. Data on the lesion size, including digital color photography, lesion regression or recurrence, and complete ophthalmic examination were recorded at the time of injection and after a week or two until resolution or surgical excision. Success was defined as at least 80% decrease in size with no recurrence. Resolution of the lesion was found in 35 cases after one or two injections, with a mean time to resolution of15.27Ā±6.12 days. Subcutaneous injection of the steroid triamcinolone acetonide in primary and recurrent chalazion appears to be a simple and efficacious therapeutic option for chalazion.Cilj studije bio je procijeniti uÄinkovitost intralezijskog injektiranja triamcinolon acetonida kod primarnog i recidivirajuÄeg halaziona. U ispitivanje je bilo ukljuÄeno 30 bolesnika s primarnim i recidivirajuÄim halazionom (37 sluÄajeva) i 24 bolesnika kao kontrolna skupina. Bolesnici s primarnim i recidivirajuÄim halazionom primili su intralezijsku injekciju 0,1 do 0,2 mL triamcinolon acetonida (40 mg/mL), dok su bolesnici kontrolne skupine primili intralezijsku injekciju 0,1 do 0,2 mL 0,9%-tne NaCl. Podatci o veliÄini lezije, ukljuÄujuÄi digitalnu fotografiju u boji, regresiji ili recidivu lezije te o cjelokupnom oftalmoloÅ”kom pregledu bilježili su se u vrijeme injektiranja te nakon jednog ili dva tjedna do povlaÄenja ili kirurÅ”kog odstranjenja lezije. UspjeÅ”nost je definirana kao najmanje 80%-tno smanjenje veliÄine lezije bez recidiva. PovlaÄenje lezije utvrÄeno je u 35 sluÄajeva nakon jedne ili dvije injekcije, srednje vrijeme do povlaÄenja od 15,27Ā±6,12 dana. Potkožno injektiranje steroida triamcinolon acetonida kod primarnog i recidivirajuÄeg halaziona pokazalo se jednostavnom i uÄinkovitom terapijom za halazion
Intralezijska injekcija triamcinolon acetonida u lijeÄenju halaziona
The aim of the study was to evaluate the efficacy of intralesional triamcinolone acetonide injection in primary and recurrent chalazion. The study included 30 patients with primary and recurrent chalazion (37 cases) and 24 patients as a control group. Patients with primary and recurrent chalazion received intralesional injection of 0.1 to 0.2 mL triamcinolone acetonide (40 mg/mL). Control group received intralesional injection of 0.1 to 0.2 mL 0.9% NaCl. Data on the lesion size, including digital color photography, lesion regression or recurrence, and complete ophthalmic examination were recorded at the time of injection and after a week or two until resolution or surgical excision. Success was defined as at least 80% decrease in size with no recurrence. Resolution of the lesion was found in 35 cases after one or two injections, with a mean time to resolution of15.27Ā±6.12 days. Subcutaneous injection of the steroid triamcinolone acetonide in primary and recurrent chalazion appears to be a simple and efficacious therapeutic option for chalazion.Cilj studije bio je procijeniti uÄinkovitost intralezijskog injektiranja triamcinolon acetonida kod primarnog i recidivirajuÄeg halaziona. U ispitivanje je bilo ukljuÄeno 30 bolesnika s primarnim i recidivirajuÄim halazionom (37 sluÄajeva) i 24 bolesnika kao kontrolna skupina. Bolesnici s primarnim i recidivirajuÄim halazionom primili su intralezijsku injekciju 0,1 do 0,2 mL triamcinolon acetonida (40 mg/mL), dok su bolesnici kontrolne skupine primili intralezijsku injekciju 0,1 do 0,2 mL 0,9%-tne NaCl. Podatci o veliÄini lezije, ukljuÄujuÄi digitalnu fotografiju u boji, regresiji ili recidivu lezije te o cjelokupnom oftalmoloÅ”kom pregledu bilježili su se u vrijeme injektiranja te nakon jednog ili dva tjedna do povlaÄenja ili kirurÅ”kog odstranjenja lezije. UspjeÅ”nost je definirana kao najmanje 80%-tno smanjenje veliÄine lezije bez recidiva. PovlaÄenje lezije utvrÄeno je u 35 sluÄajeva nakon jedne ili dvije injekcije, srednje vrijeme do povlaÄenja od 15,27Ā±6,12 dana. Potkožno injektiranje steroida triamcinolon acetonida kod primarnog i recidivirajuÄeg halaziona pokazalo se jednostavnom i uÄinkovitom terapijom za halazion
Sigurnost i uÄinkovit ostfiksne kombinacije (travoprost 0,004%/timolol 0,5%) umjesto monoterapije u Å”estomjeseÄnom periodu praÄenja
Purpose: To assess the safety and efficacy of changing antiglaucoma therapy to the travoprost 0,004%/timolol 0,5% (TTF C) fixed combination from previous monotherapies.
Methods: Prospective, open-label, observational, multicenter cohort. A change was done from prior monotherapy at day 0 to TTF C dosed once a day, regardless in the evening or in the morning, without washout period. Active evaluation of systemic and local tolerability (adverse events), and efficacy ie. intraocular pressure (IOP) lowering was done at control 1 (day 30), control 2 (day 90) and control 3 (day 120).
Results: 40/155/170 patients (79/309/339 eyes) completed the study (120 days/ 90 days/baseline, respectfully). At control 1 excluded were patients with low tolerability (severe hyperemia (6 patients), discomfort (4), chest pain (1)) and non responders (IOP lowering less than 15% from baseline IOP or target IOP >18 mmHg (4 patients)). Mean IOP at control 1 was 15,92Ā±1,85 mm Hg (21,66% reduction) for 155 patients (non responders excluded), at control 2 was for 155 patients 15,67Ā±2,17 mm Hg (21,14% reduction), and at control 3 for 40 patients 16,28Ā±1,59 mm Hg (19,86% reduction). At control 2 analysis of IOP reduction by 4 groups of previous monotherapy (timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), and travoprost 0,004% (N=43/85) was performed. 40 patients/79 eyes endured to control 3 (after day 90 free samples were not available for all patients). Analysis of IOP reduction by 4 groups of previous monotherapy medications was performed (timolol 0,5%(N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23)).
Conclusions: Changing patients from prior monotherapy to TTF C can provide on average a further reduction in IOP, while demonstrating a favorable safety profile.CILJ: Zabilježiti sigurnost i uÄinkovitost promjene antiglaukomske terapije u travoprost 0,004%/timolol 0,5% (TTF C) fiksnu kombinaciju s prethodnih monoterapija.
METODE: Prospektivna, otvorena, opservacijska, multicentriÄna populacija. Promjena s prethodne monoterapije na dan 0 u TTF C, doziran jednom dnevno, ili ujutro ili naveÄer, bez perioda ispiranja. Aktivno je ocijenjena sistemska i lokalna podnoÅ”ljivost (popratne pojave), i uÄinkovitost tj.sniženje intraokularnog tlaka (IOT) na prvoj kontroli (dan 30), drugoj kontroli (dan 90) i treÄoj kontroli (dan 120).
REZULTATI: 40/155/170 bolesnika (79/309/339 oÄiju) zavrÅ”ilo je studiju (120 dana/ 90 dana/poÄetak). Na prvoj kontroli iskljuÄeni su svi bolesnici koji su slabo podnosili lijek: ozbiljna hiperemija (6 bolesnika), neugoda (4), bol u prsiÅ”tu (1) i ne- responderi tj. sniženje IOT-a manje od 15% od poÄetnog IOT ili ciljnog IOT >18 mmHg (4 bolesnika). ProsjeÄni IOT na prvoj kontroli je bio 15,92Ā±1,85 mm Hg (21,66% sniženja) kod 155 bolesnika (iskljuÄeni ne-responderi), na drugoj kontroli je kod 155 bolesnika bio 15,67Ā±2,17 mm Hg (21,14% sniženja), i na treÄoj kontroli kod 40 bolesnika 16,28Ā±1,59 mm Hg (19,86% sniženja). Na drugoj kontroli je uÄinjena analiza sniženja IOT-a u 4 grupe prethodno koriÅ”tene monoterapije: timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), i travoprost 0,004% (N=43/85). 40 bolesnika/79 oÄiju praÄeno je do treÄe kontrole. UÄinjena je analiza sniženja IOT-a u 4 grupe prethodno koriÅ”tene monoterapije: timolol 0,5% (N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23).
ZakljuÄak: Promjena terapije s prethodne monoterapije u TTF C može u prosjeku omoguÄiti dodatno sniženje IOT-a, uz zadovoljavajuÄi profil sigurnosti
Sigurnost i uÄinkovit ostfiksne kombinacije (travoprost 0,004%/timolol 0,5%) umjesto monoterapije u Å”estomjeseÄnom periodu praÄenja
Purpose: To assess the safety and efficacy of changing antiglaucoma therapy to the travoprost 0,004%/timolol 0,5% (TTF C) fixed combination from previous monotherapies.
Methods: Prospective, open-label, observational, multicenter cohort. A change was done from prior monotherapy at day 0 to TTF C dosed once a day, regardless in the evening or in the morning, without washout period. Active evaluation of systemic and local tolerability (adverse events), and efficacy ie. intraocular pressure (IOP) lowering was done at control 1 (day 30), control 2 (day 90) and control 3 (day 120).
Results: 40/155/170 patients (79/309/339 eyes) completed the study (120 days/ 90 days/baseline, respectfully). At control 1 excluded were patients with low tolerability (severe hyperemia (6 patients), discomfort (4), chest pain (1)) and non responders (IOP lowering less than 15% from baseline IOP or target IOP >18 mmHg (4 patients)). Mean IOP at control 1 was 15,92Ā±1,85 mm Hg (21,66% reduction) for 155 patients (non responders excluded), at control 2 was for 155 patients 15,67Ā±2,17 mm Hg (21,14% reduction), and at control 3 for 40 patients 16,28Ā±1,59 mm Hg (19,86% reduction). At control 2 analysis of IOP reduction by 4 groups of previous monotherapy (timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), and travoprost 0,004% (N=43/85) was performed. 40 patients/79 eyes endured to control 3 (after day 90 free samples were not available for all patients). Analysis of IOP reduction by 4 groups of previous monotherapy medications was performed (timolol 0,5%(N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23)).
Conclusions: Changing patients from prior monotherapy to TTF C can provide on average a further reduction in IOP, while demonstrating a favorable safety profile.CILJ: Zabilježiti sigurnost i uÄinkovitost promjene antiglaukomske terapije u travoprost 0,004%/timolol 0,5% (TTF C) fiksnu kombinaciju s prethodnih monoterapija.
METODE: Prospektivna, otvorena, opservacijska, multicentriÄna populacija. Promjena s prethodne monoterapije na dan 0 u TTF C, doziran jednom dnevno, ili ujutro ili naveÄer, bez perioda ispiranja. Aktivno je ocijenjena sistemska i lokalna podnoÅ”ljivost (popratne pojave), i uÄinkovitost tj.sniženje intraokularnog tlaka (IOT) na prvoj kontroli (dan 30), drugoj kontroli (dan 90) i treÄoj kontroli (dan 120).
REZULTATI: 40/155/170 bolesnika (79/309/339 oÄiju) zavrÅ”ilo je studiju (120 dana/ 90 dana/poÄetak). Na prvoj kontroli iskljuÄeni su svi bolesnici koji su slabo podnosili lijek: ozbiljna hiperemija (6 bolesnika), neugoda (4), bol u prsiÅ”tu (1) i ne- responderi tj. sniženje IOT-a manje od 15% od poÄetnog IOT ili ciljnog IOT >18 mmHg (4 bolesnika). ProsjeÄni IOT na prvoj kontroli je bio 15,92Ā±1,85 mm Hg (21,66% sniženja) kod 155 bolesnika (iskljuÄeni ne-responderi), na drugoj kontroli je kod 155 bolesnika bio 15,67Ā±2,17 mm Hg (21,14% sniženja), i na treÄoj kontroli kod 40 bolesnika 16,28Ā±1,59 mm Hg (19,86% sniženja). Na drugoj kontroli je uÄinjena analiza sniženja IOT-a u 4 grupe prethodno koriÅ”tene monoterapije: timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), i travoprost 0,004% (N=43/85). 40 bolesnika/79 oÄiju praÄeno je do treÄe kontrole. UÄinjena je analiza sniženja IOT-a u 4 grupe prethodno koriÅ”tene monoterapije: timolol 0,5% (N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23).
ZakljuÄak: Promjena terapije s prethodne monoterapije u TTF C može u prosjeku omoguÄiti dodatno sniženje IOT-a, uz zadovoljavajuÄi profil sigurnosti
PREVALENCE OF SIDEROPENIA AND SIDEROPENIC ANEMIA IN PATIENTS HOSPITALIZED FOR HEART FAILURE
Zatajivanje srca razlog je sve veÄeg broja hospitalizacija te je jedan od vodeÄih uzroka smrti u svijetu, naroÄito zapadnim zemljama. Sideropenija sa ili bez anemije uÄestali je komorbiditet te potencijalna terapijska meta u bolesnika sa ZS. NastojeÄi utvrditi meÄusobnu povezanost, u periodu od 1. rujna do 1. prosinca 2019. godine analizirali smo povijest bolesti 150 bolesnika hospitaliziranih zbog akutizacije ZS. UtvrÄena je visoka prevalencija anemije i sideropenije meÄu hospitaliziranim bolesnicima, a muÅ”karci su, u oba sluÄaja viÅ”e prevladavali. TakoÄer je uÄestalost apsolutne sideropenije, koja korelira sa težom kliniÄkom slikom, bila veÄa od funkcionalne sideropenije. UsporeÄivanjem vrijednosti osnovnih kliniÄkih karakteristika i laboratorijskih parametara u bolesnika sa sideropenijom i bez sideropenije, hospitaliziranih zbog ZS, utvrdili smo signifikantno viÅ”e vrijednosti frekvencije srca (p=0,016) i serumskoga kreatinina (p=0,046) u prvoj grupi. S druge strane, statistiÄki znaÄajno niže vrijednosti serumskoga željeza (p=0,045) i feritina (p<0,001) pogorÅ”avali su veÄ i ovako naruÅ”enu kvalitetu života bolesnika sa sideropenijom. GraniÄno reducirana bubrežna funkcija sideropeniÄnih bolesnika, opravdavala je bubrežnu ozljedu kao važan komorbiditet u ZS (kardiorenalni sindrom). UzimajuÄi u obzir promijenjenu bubrežnu funkciju, bolesnici sa sideropenijom signifikantno su manje primali ACE-I (p=0,049). Ukupna smrtnost iznosila je 16,7% u bolesnika hospitaliziranih zbog ZS.Heart failure is the cause of an increasing number of hospitalizations and is one of the leading causes of death in the world, especially in Western countries. Iron deficiency, with or without anemia is a common comorbidity and a potential therapeutic target in patients with heart failure. In an effort to establish the interrelationship, in the period from September 1 to December 1, 2019, we analyzed the medical history of 150 patients hospitalized due to decompensated heart failure. A high prevalence of anemia and iron deficiency was found among hospitalized patients, and men were, in both cases, more prevalent. Also, the incidence of absolute iron deficiency, which correlates with a more severe clinical presentation, was higher than functional iron deficiency. By comparing the values of basic clinical characteristics and laboratory parameters in patients with and without iron deficiency, hospitalized for heart failure, we found significantly higher values of heart rate (p=0.016) and serum creatinine (p=0.046) in the first group. On the other hand, statistically significantly lower values of serum iron (p=0.045) and ferritin (p<0.001) worsened the already impaired quality of life of patients with iron deficiency. Reduced renal function in iron deficiency patients justified renal injury as an important comorbidity in heart failure (cardiorenal syndrome). Considering altered renal function, patients with iron deficiency received significantly less ACE-I (p=0.049). The overall mortality was 16.7% in patients hospitalized for heart failure
PREVALENCE OF SIDEROPENIA AND SIDEROPENIC ANEMIA IN PATIENTS HOSPITALIZED FOR HEART FAILURE
Zatajivanje srca razlog je sve veÄeg broja hospitalizacija te je jedan od vodeÄih uzroka smrti u svijetu, naroÄito zapadnim zemljama. Sideropenija sa ili bez anemije uÄestali je komorbiditet te potencijalna terapijska meta u bolesnika sa ZS. NastojeÄi utvrditi meÄusobnu povezanost, u periodu od 1. rujna do 1. prosinca 2019. godine analizirali smo povijest bolesti 150 bolesnika hospitaliziranih zbog akutizacije ZS. UtvrÄena je visoka prevalencija anemije i sideropenije meÄu hospitaliziranim bolesnicima, a muÅ”karci su, u oba sluÄaja viÅ”e prevladavali. TakoÄer je uÄestalost apsolutne sideropenije, koja korelira sa težom kliniÄkom slikom, bila veÄa od funkcionalne sideropenije. UsporeÄivanjem vrijednosti osnovnih kliniÄkih karakteristika i laboratorijskih parametara u bolesnika sa sideropenijom i bez sideropenije, hospitaliziranih zbog ZS, utvrdili smo signifikantno viÅ”e vrijednosti frekvencije srca (p=0,016) i serumskoga kreatinina (p=0,046) u prvoj grupi. S druge strane, statistiÄki znaÄajno niže vrijednosti serumskoga željeza (p=0,045) i feritina (p<0,001) pogorÅ”avali su veÄ i ovako naruÅ”enu kvalitetu života bolesnika sa sideropenijom. GraniÄno reducirana bubrežna funkcija sideropeniÄnih bolesnika, opravdavala je bubrežnu ozljedu kao važan komorbiditet u ZS (kardiorenalni sindrom). UzimajuÄi u obzir promijenjenu bubrežnu funkciju, bolesnici sa sideropenijom signifikantno su manje primali ACE-I (p=0,049). Ukupna smrtnost iznosila je 16,7% u bolesnika hospitaliziranih zbog ZS.Heart failure is the cause of an increasing number of hospitalizations and is one of the leading causes of death in the world, especially in Western countries. Iron deficiency, with or without anemia is a common comorbidity and a potential therapeutic target in patients with heart failure. In an effort to establish the interrelationship, in the period from September 1 to December 1, 2019, we analyzed the medical history of 150 patients hospitalized due to decompensated heart failure. A high prevalence of anemia and iron deficiency was found among hospitalized patients, and men were, in both cases, more prevalent. Also, the incidence of absolute iron deficiency, which correlates with a more severe clinical presentation, was higher than functional iron deficiency. By comparing the values of basic clinical characteristics and laboratory parameters in patients with and without iron deficiency, hospitalized for heart failure, we found significantly higher values of heart rate (p=0.016) and serum creatinine (p=0.046) in the first group. On the other hand, statistically significantly lower values of serum iron (p=0.045) and ferritin (p<0.001) worsened the already impaired quality of life of patients with iron deficiency. Reduced renal function in iron deficiency patients justified renal injury as an important comorbidity in heart failure (cardiorenal syndrome). Considering altered renal function, patients with iron deficiency received significantly less ACE-I (p=0.049). The overall mortality was 16.7% in patients hospitalized for heart failure
PREVALENCE OF SIDEROPENIA AND SIDEROPENIC ANEMIA IN PATIENTS HOSPITALIZED FOR HEART FAILURE
Zatajivanje srca razlog je sve veÄeg broja hospitalizacija te je jedan od vodeÄih uzroka smrti u svijetu, naroÄito zapadnim zemljama. Sideropenija sa ili bez anemije uÄestali je komorbiditet te potencijalna terapijska meta u bolesnika sa ZS. NastojeÄi utvrditi meÄusobnu povezanost, u periodu od 1. rujna do 1. prosinca 2019. godine analizirali smo povijest bolesti 150 bolesnika hospitaliziranih zbog akutizacije ZS. UtvrÄena je visoka prevalencija anemije i sideropenije meÄu hospitaliziranim bolesnicima, a muÅ”karci su, u oba sluÄaja viÅ”e prevladavali. TakoÄer je uÄestalost apsolutne sideropenije, koja korelira sa težom kliniÄkom slikom, bila veÄa od funkcionalne sideropenije. UsporeÄivanjem vrijednosti osnovnih kliniÄkih karakteristika i laboratorijskih parametara u bolesnika sa sideropenijom i bez sideropenije, hospitaliziranih zbog ZS, utvrdili smo signifikantno viÅ”e vrijednosti frekvencije srca (p=0,016) i serumskoga kreatinina (p=0,046) u prvoj grupi. S druge strane, statistiÄki znaÄajno niže vrijednosti serumskoga željeza (p=0,045) i feritina (p<0,001) pogorÅ”avali su veÄ i ovako naruÅ”enu kvalitetu života bolesnika sa sideropenijom. GraniÄno reducirana bubrežna funkcija sideropeniÄnih bolesnika, opravdavala je bubrežnu ozljedu kao važan komorbiditet u ZS (kardiorenalni sindrom). UzimajuÄi u obzir promijenjenu bubrežnu funkciju, bolesnici sa sideropenijom signifikantno su manje primali ACE-I (p=0,049). Ukupna smrtnost iznosila je 16,7% u bolesnika hospitaliziranih zbog ZS.Heart failure is the cause of an increasing number of hospitalizations and is one of the leading causes of death in the world, especially in Western countries. Iron deficiency, with or without anemia is a common comorbidity and a potential therapeutic target in patients with heart failure. In an effort to establish the interrelationship, in the period from September 1 to December 1, 2019, we analyzed the medical history of 150 patients hospitalized due to decompensated heart failure. A high prevalence of anemia and iron deficiency was found among hospitalized patients, and men were, in both cases, more prevalent. Also, the incidence of absolute iron deficiency, which correlates with a more severe clinical presentation, was higher than functional iron deficiency. By comparing the values of basic clinical characteristics and laboratory parameters in patients with and without iron deficiency, hospitalized for heart failure, we found significantly higher values of heart rate (p=0.016) and serum creatinine (p=0.046) in the first group. On the other hand, statistically significantly lower values of serum iron (p=0.045) and ferritin (p<0.001) worsened the already impaired quality of life of patients with iron deficiency. Reduced renal function in iron deficiency patients justified renal injury as an important comorbidity in heart failure (cardiorenal syndrome). Considering altered renal function, patients with iron deficiency received significantly less ACE-I (p=0.049). The overall mortality was 16.7% in patients hospitalized for heart failure
Agility Testing in Youth Football (Soccer) Players : Evaluating Reliability, Validity, and Correlates of Newly Developed Testing Protocols
Reactive agility (RAG) and change of direction speed (CODS) are important determinants of success in football (soccer), but there is an evident lack of information on reliable and valid football-specific testing procedures which will be applicable in defining sport-specific RAG and CODS in youth players. This study evaluated reliability and construct validity of newly developed tests of football-specific RAG (FS_RAG) and CODS (FS_CODS), which involved the ball kicking football technique. Additionally, factors associated with FS_RAG and FS_CODS were evaluated. The participants were youth football players (n = 59; age: 13.40 Ā± 1.25 years) divided according to their age into U13 (11ā12 years of age; n = 29), and U15 (13ā14 years of age; n = 30) categories. Additionally, performance levels (starters [first-team] vs. non-starters [substitutes]) were observed in each age category. The dependent variables were newly developed FS_RAG and FS_CODS tests. The independent variables were sprinting capacities over 10 and 20 meters (S10M, S20M), countermovement jump (CMJ), the reactive strength index (RSI), and a generic CODS test of 20 yards (20Y). The newly developed FS_CODS and FS_RAG were observed as dependent variables. Results showed appropriate intra-testing and inter-testing reliability of the FS_RAG and FS_CODS, with somewhat better reliability of the FS_CODS (ICC=0.82 and 0.79, respectively). Additionally, better reliability was evidenced in U15 than in U13 (ICC: 0.82ā0.85, and 0.78-0.80 for U15 and U13, respectively). Independent samples t-test indicated significant differences between U13 and U15 in S10 (t-test: 3.57,Ā pĀ < 0.001), S20M (t-test: 3.13,Ā pĀ < 0.001), 20Y (t-test: 4.89,Ā pĀ < 0.001), FS_RAG (t-test: 3.96,Ā pĀ < 0.001), and FS_CODS (t-test: 6.42,Ā pĀ < 0.001), with better performance in U15. Starters outperformed non-starters in most capacities among U13, but only in FS_RAG among U15 (t-test: 1.56,Ā pĀ < 0.05). Multiple regression calculations indicated nonsignificant association between independent and dependent variables in U13 (FS_CODS: 19%, FS_RAG: 21% of the explained variance, bothĀ pĀ > 0.05), but independent variables explained significant proportion of both dependent variables in U15 (FS_CODS: 35%, FS_RAG: 33% explained variance, bothĀ pĀ < 0.05). The study confirmed the applicability of newly developed tests in distinguishing studied age categories of players. Results indicate that superiority in all studied fitness capacities is translated into performance level in U13. Meanwhile, FS_RAG seems to be important determinant of quality in U15
Non-alcoholic fatty liver disease and transient elastography
Nonalcoholic fatty liver disease (NAFLD) is a serious condition that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is associated with metabolic syndrome (MetS) and all of its components. According to data, around 25-30% of population has NAFLD. Giving the growing incidence of MetS, obesity and diabetes mellitus type 2, NAFLD related terminal-stage liver disease is becoming prevailing indication for liver transplantation. In order to prevent terminal stage of this disease, it is crucial to determine those that are in risk group, to modify their risk factors and monitor their potential progression. In the absence of other causes of chronic liver disease, the prime diagnosis of NAFLD in daily clinical practice includes anamnesis, laboratory results (increased levels of aminotransferases and gammaglutamil transferases) and imaging methods. The biggest challenge with NAFLD patients is to differentiate simple steatosis from nonalcoholic steatohepatitis, and detection of fibrosis, that is the main driver in NAFLD progression. The gold standard for NAFLD diagnosis still remains the liver biopsy (LB). However, in recent years many noninvasive methods were invented, such as transient elastography (TE). TE (FibroScanĀ®, Echosens, Paris, France) is used for diagnosis of pathological differences of liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). Investigations in the last years have confirmed that elastographic parameters of steatsis (CAP) and fibrosis (LSM) are reliable biomarkers to non-invasively assess liver steatosis and fibrosis respectively in NAFLD patients. A quick, straightforward and non-invasive method for NAFLD screening in patients with MetS components is TE-CAP. Once diagnosed, the next step is to determine the presence of fibrosis by LSM which should point out high risk patients. Those patients should be referred to hepatologists. LB may be avoided in a substantial number of patients if TE with CAP is used for screening
Slagalica nasljeÄa : priruÄnik za opismenjavanje iz medicinske genetike
"Slagalica nasljeÄa" - priruÄnik za opismenjavanje iz medicinske genetike
ima tri namjene. Prije svega, on je edukativna slikovnica za studente,
lijeÄnike i pacijente, ali i druge zainteresirane pojedince jer su u njoj
kroz ilustracije objaÅ”njene osnove genetike Äovjeka, kao i osnove medicinske
genetike. Od toga kako prepoznati osobu s genetiÄkim poremeÄajem, kako
nastaju i koje vrste genetiÄkih poremeÄaja postoje pa sve do toga na koji ih
naÄin možemo dijagnosticirati. Nadalje, nakon svake ilustracije na pojedinoj
stranici nalaze se definicije 79 pojmova iz medicinske genetike koje Äine
tezaurus za studente, lijeÄnike i pacijente koji se na bilo koji naÄin
susreÄu s genetiÄkim poremeÄajima. Naposljetku, ova knjiga sadrži i primjere
reÄenica u koje su ubaÄeni struÄni pojmovi iz medicinske genetike, a koji su
namijenjeni studentima prilikom savladavanja komunikacijskih vjeŔtina na
kolegiju Medicinska genetika, ali i lijeÄnicima prilikom informiranja svojih
pacijenata o (moguÄem) genetiÄkom poremeÄaju.
Uz kreatoricu ideje i urednicu izdanja, doc. dr. sc. Ninu Perezu, autori
izdanja su studenti Ŕeste godine Integriranog preddiplomskog i diplomskog
sveuÄiliÅ”nog studija Medicina i prof. dr. sc. SaÅ”a OstojiÄ